share_log

康方生物：截至二零二四年二月二十九日止月份股份發行人的證券變動月報表

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

香港交易所 ·  Mar 5 05:06
Summary by Moomoo AI
康方生物科技（開曼）有限公司於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股份變動情況。報告顯示，公司的法定/註冊股本在本月內無增減，結存維持在5,000,000,000股，每股面值0.00001美元，總額為50,000美元。此外，公司的已發行股份也未見變動。報告中提及的股份期權計劃顯示，截至本月底，根據2022年6月28日採納的首次公開發售後購股權計劃，公司擁有450,000股份期權，本月內無新增或註銷，可能發行的新股份數目為39,000股。公司確認，所有本月發行的證券均已獲得董事會的正式授權，並符合相關上市規則的要求。
康方生物科技（開曼）有限公司於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股份變動情況。報告顯示，公司的法定/註冊股本在本月內無增減，結存維持在5,000,000,000股，每股面值0.00001美元，總額為50,000美元。此外，公司的已發行股份也未見變動。報告中提及的股份期權計劃顯示，截至本月底，根據2022年6月28日採納的首次公開發售後購股權計劃，公司擁有450,000股份期權，本月內無新增或註銷，可能發行的新股份數目為39,000股。公司確認，所有本月發行的證券均已獲得董事會的正式授權，並符合相關上市規則的要求。
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 March 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 29 February 2024. The report showed that the company's regulated/registered share capital did not increase during the month, with deposits held at 5,000,000,000 shares with a face value of $0.00001 per share, totaling $50,000. In addition, the company's issued shares were unchanged. The share option plans mentioned in the report show that, as of the end of this month, the Company had 450,000 share options under the Initial Public Offering Option Plan adopted on June 28, 2022, with no additions or write-offs during the month, and the number of new shares that may be issued is 39,000 shares. The Company confirms that all securities issued this month have been formally authorized by the Board of Directors and meet the requirements of the relevant Listing Rules.
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 March 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 29 February 2024. The report showed that the company's regulated/registered share capital did not increase during the month, with deposits held at 5,000,000,000 shares with a face value of $0.00001 per share, totaling $50,000. In addition, the company's issued shares were unchanged. The share option plans mentioned in the report show that, as of the end of this month, the Company had 450,000 share options under the Initial Public Offering Option Plan adopted on June 28, 2022, with no additions or write-offs during the month, and the number of new shares that may be issued is 39,000 shares. The Company confirms that all securities issued this month have been formally authorized by the Board of Directors and meet the requirements of the relevant Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more